Drugs / Nemvaleukin Alfa
Nemvaleukin Alfa
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04592653 | Sep 2020 → Jul 2024 overdue | neoplasm | Mural Oncology, Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03861793 | Feb 2019 → Mar 2023 | cancer | Mural Oncology, Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT02799095 | Sep 2016 → Mar 2023 | cancer | Mural Oncology, Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04830124 | Sep 2021 → May 2025 | cutaneous melanoma, mucosal melanoma | Mural Oncology, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT04144517 | Feb 2020 → Oct 2021 | head and neck squamous cell carcinoma | Mural Oncology, Inc | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05092360 | Jan 2022 → Jan 2025 | fallopian tube carcinoma, primary peritoneal carcinoma, refractory malignant neoplasm | Mural Oncology, Inc | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nemvaleukin Alfa | “Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds to the intermediate-affinity interleukin-2 receptor, preferentially activating...” PMID 39567211 ↗ Nov 2024 |
| Known as | ALKS 4230 | “A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer” NCT04144517 ↗ |
| Known as | nemvaleukin | “Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds to the intermediate-affinity interleukin-2 receptor, preferentially activating...” PMID 39567211 ↗ Nov 2024 |
| Known as | RDB-1450 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095282 ↗ |
| Action | Activate | “selectively binds to the intermediate-affinity interleukin-2 receptor, preferentially activating CD8+ T cells and natural killer cells” PMID 39567211 ↗ Nov 2024 |
| Modality | Protein / enzyme biologic | “Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).” PMID 39567211 ↗ Nov 2024 |
| Route | Intravenous | “Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period” NCT02799095 ↗ |